metvixia
Metvixia (Methyl Aminolevulinate Hydrochloride) is a porphyrin precursor used to treat Actinic Keratosis.
Methyl Aminolevulinate Hydrochloride · by Galderma Labs LP
Key facts
- Active ingredient
- Methyl Aminolevulinate Hydrochloride
- Drug class
- Porphyrin Precursor
- Form
- Topical
- Strength
- Methyl Aminolevulinate Hydrochloride EQ 16.8% Base
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- actinic keratosis
- Manufacturer
- Galderma Labs LP
- FDA application
- NDA021415
- Availability
- Discontinued (per FDA)
Drug class
May treat (source: NIH RxClass)
Dosage forms
Topical
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Metvixia treat?
- Metvixia (Methyl Aminolevulinate Hydrochloride) may be used to treat actinic keratosis, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- Is there a coupon or discount for Metvixia?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Metvixia. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Metvixia?
- Metvixia is marketed by Galderma Labs LP. You can see Galderma Labs LP's full profile, rating, and other products on pharmaranks.
- Is Metvixia a brand-name or generic drug?
- Metvixia is a brand-name product with the active ingredient Methyl Aminolevulinate Hydrochloride.
- Is Metvixia available over the counter?
- No. Metvixia is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Metvixia come in?
- Metvixia is currently marketed as topical, per the FDA's National Drug Code Directory.
- What class of drug is Metvixia?
- Metvixia is classified as porphyrin precursor, per the FDA's Established Pharmacologic Class.
- Is Metvixia FDA-registered?
- Metvixia is on record with the U.S. FDA under application number NDA021415. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about METHYL AMINOLEVULINATE HYDROCHLORIDE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 25 reports naming METHYL AMINOLEVULINATE HYDROCHLORIDE — the active ingredient in Metvixia, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- malaise3 reports
- eczema2 reports
- erythema2 reports
- headache2 reports
- malignant neoplasm progression2 reports
- nausea2 reports
- oedema peripheral2 reports
- pain of skin2 reports
Read these as a signal, not a rate. A report does not mean METHYL AMINOLEVULINATE HYDROCHLORIDE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Metvixia head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
metvixia
New